02Aug
FDA Issues Cannabidiol Marketing Warning as Congressional Pressure for Action Continues
Following through with its promise to take enforcement actions against companies marketing cannabis-derived products that could put consumers at risk, the Food and Drug Administration (FDA) recently issued a warning letter to Curaleaf Inc., a...
By:
Wilson Sonsini Goodrich & Rosati
Related
In the last week, a new type of BIPA case has emerged that should be of interest to companies involv...
Read More >
N.C. Business Court Addresses the Scope of a Judicial Appraisal Proceeding- In Reynolds American In...
Read More >
Supreme Judicial Court Issues Order Signaling End of Deadline and Statute of Limitations Extensions ...
Read More >
The Benefit of Knowing- Monday morning quarterbacking – the connotations are anything but positive...
Read More >
As you are aware from these pages, Connecticut’s General Assembly produced a plethora of bills affe...
Read More >
As in implementing regulation of Law of the Republic Indonesia No.5 of 1999 on the Prohibition of Mo...
Read More >